BibTex format
@article{Sconza:2026:10.1097/QAD.0000000000004461,
author = {Sconza, R and Taylor, GP and Ene, L and Kahlert, C and van, der Wekken-Pas L and Renaud, F and Thorne, C and Townsend, CL and Epidemiology, of Pregnancy and Paediatric Infections International Cohort Collaboration EPPICC and London HIV Perinatal Research Group LHPRG},
doi = {10.1097/QAD.0000000000004461},
journal = {AIDS},
pages = {831--839},
title = {Dosing of ritonavir-boosted darunavir for treatment of HIV in pregnancy.},
url = {http://dx.doi.org/10.1097/QAD.0000000000004461},
volume = {40},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - OBJECTIVE: To assess the effectiveness of once- and twice-daily ritonavir-boosted darunavir (DRV/r)-containing regimens for treating HIV in pregnancy to inform the 2025 World Health Organization antiretroviral treatment guidelines update. DESIGN: Analysis of pooled data from two observational study networks with sites in Romania, Switzerland, and the United Kingdom. METHODS: Pregnancies resulting in a live birth or stillbirth in women receiving 800/100mg DRV/r once-daily or 600/100mg twice-daily during pregnancy were included. The primary outcome was viral suppression (<50copies/ml) near delivery (from 28days prior to 7days after delivery). RESULTS: Among 162 women on once-daily DRV/r, 95% were virally suppressed near delivery, with no difference between those on DRV/r from conception (95%, 113/119) and those who started on or switched to DRV/r during pregnancy (95%, 41/43). Among 27 women on twice-daily DRV/r, 78% were virally suppressed near delivery. Most women remained on the same DRV/r regimen until delivery, and there were no vertical transmissions. Darunavir drug concentrations for the limited number of pregnancies with data available fell within the expected ranges. CONCLUSIONS: This analysis provides some reassurance that once-daily DRV/r can be used successfully in pregnancy. However, given the possibility of reduced drug levels in pregnancy with once-daily dosing, viral load monitoring during pregnancy remains essential. Surveillance of pregnancies in women receiving once-daily DRV/r is needed to further support the use of this dosing during pregnancy.
AU - Sconza,R
AU - Taylor,GP
AU - Ene,L
AU - Kahlert,C
AU - van,der Wekken-Pas L
AU - Renaud,F
AU - Thorne,C
AU - Townsend,CL
AU - Epidemiology,of Pregnancy and Paediatric Infections International Cohort Collaboration EPPICC and London HIV Perinatal Research Group LHPRG
DO - 10.1097/QAD.0000000000004461
EP - 839
PY - 2026///
SP - 831
TI - Dosing of ritonavir-boosted darunavir for treatment of HIV in pregnancy.
T2 - AIDS
UR - http://dx.doi.org/10.1097/QAD.0000000000004461
UR - https://www.ncbi.nlm.nih.gov/pubmed/41670404
VL - 40
ER -